UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

NDA FilingUGN-103Positive

AI Analysis

Summary

UroGen submitted an NDA to the FDA for UGN-103, an investigational treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. This regulatory filing represents a significant milestone in the drug's development pathway.

Importance:7/10

Sentiment:

0.60

NDA_FilingBladder_CancerNMIBCRegulatory_Milestone

Related Companies

$URGN

Read the original article

Published by GlobeNewswire Clinical Studies on August 17, 2026 12:00 PM

Read Original